EE393 Assessing Cost-Effectiveness in Diabetes Management: A US Healthcare Payer’s Perspective on 15MG Tirzepatide Versus 1MG Semaglutide
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.689
https://www.valueinhealthjournal.com/article/S1098-3015(24)00804-0/fulltext
Section Title :
Section Order :
10160
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00804-0&doi=10.1016/j.jval.2024.03.689